NCT06986096 Lifestyle for the BRAin Health - Nutrition and Exercise Training Intervention
| NCT ID | NCT06986096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Slovak Academy of Sciences |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-09-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Due to the increasing incidence of dementia and the lack of causal treatment, non-pharmacological interventions represent an attractive and effective therapeutic strategy of neurodegenerative diseases, such as Alzheimer's disease. The aim of the study is to assess the impact of a supervised 9-month intervention with aerobic-strength training and nutritional counseling compared to cognitive training and stretching on the brain, cognitive and motor functions, metabolism, physical fitnes and plasma markers of neurodegenertion in older adults at increased risk of developing Alzheimer's disease.
Eligibility Criteria
Inclusion Criteria: * Non-smokers * Signed informed consent * Presence of subjective or mild cognitive impairment (SCI/aMCI) * Elevated levels of selected biomarkers confirming the presence of a pathological process characteristic of Alzheimer's disease * Absence of any psychological, sociological, or geographical factors that could jeopardize participation in the project. Exclusion Criteria: * Presence of severe cardiovascular, liver, or kidney diseases; advanced or poorly controlled diabetes mellitus (HbA1c \>7%), treated with insulin or incretin analogs; cancer or any other severe disease as assessed by the responsible physician. A history of cancer treated with chemotherapy or radiotherapy if within less than 5 years post-treatment. * Lack of cooperation, inflexible schedule, or problematic transportation. * Insufficient functional capacity or presence of comorbidities that prevent participation in the training program (assessment by an internist, cardiologist, neurologist, orthopedic specialist, or other relevant specialists). * Presence of a pacemaker or any metal implants (contraindication for MRI examination), or allergy to local anesthetics (contraindication for muscle biopsy). * Smoking, alcohol dependence, or addiction to other narcotic substances. * Stroke or myocardial infarction within the last year. * Long-term treatment for psychiatric disorders - a depressive syndrome is not an exclusion criterion if it is compensated by therapy. * Other diseases of the musculoskeletal or nervous system that potentially interfere with the ability to exercise or cognition - such as severe arthritis, Parkinson's disease, significant essential tremor, epilepsy, etc. * Concurrent participation in another clinical study. * Therapy with cholinesterase inhibitors unless the patient is on a stable dose.
Contact & Investigator
Barbora Ukropcova, Prof.
PRINCIPAL INVESTIGATOR
Biomedical Research Center Slovak Academy of Science
Frequently Asked Questions
Who can join the NCT06986096 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 80 Years, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06986096 currently recruiting?
Yes, NCT06986096 is actively recruiting participants. Contact the research team at barbara.ukropcova@sabva.sk for enrollment information.
Where is the NCT06986096 trial being conducted?
This trial is being conducted at Bratislava, Slovakia.
Who is sponsoring the NCT06986096 clinical trial?
NCT06986096 is sponsored by Slovak Academy of Sciences. The principal investigator is Barbora Ukropcova, Prof. at Biomedical Research Center Slovak Academy of Science. The trial plans to enroll 40 participants.